Successful desensitisation to paclitaxel with omalizumab

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies

(2021) D.M. Barrios et al.   ANNALS OF ONCOLOGY

Update on omalizumab in allergen immunotherapy

(2021) Jennifer A. Dantzer et al.   Current Opinion in Allergy and Clinical Immunology

Hypersensitivity reactions to chemotherapy: an EAACI Position Paper

(2021) Mauro Pagani et al.   ALLERGY

Omalizumab for successful chemotherapy desensitisation: What we know so far

(2021) Roxana Silvia Bumbacea et al.   Clinical and Translational Allergy

Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study

(2020) Hanneke N. G. Oude Elberink et al.   Clinical and Translational Allergy

Unexpected Anaphylaxis After Completing a Desensitization Protocol to Oxaliplatin: Successful Adjuvant Use of Omalizumab

(2019) A Prieto-García et al.   JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY

Utility of Risk Stratification for Paclitaxel Hypersensitivity Reactions

(2018) Iris M. Otani et al.   Journal of Allergy and Clinical Immunology-In Practice

A Large Single-Hospital Experience Using Drug Provocation Testing and Rapid Drug Desensitization in Hypersensitivity to Antineoplastic and Biological Agents

(2018) Ricardo Madrigal-Burgaleta et al.   Journal of Allergy and Clinical Immunology-In Practice

Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions

(2016) Matthieu Picard et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

A modified protocol for rapid desensitization to chemotherapy agents

(2016) Carmen Vidal et al.   Journal of Allergy and Clinical Immunology-In Practice

Hypersensitivity reactions to oxaliplatin and other antineoplastic agents

(2008) Ekaterini Syrigou et al.   CURRENT ALLERGY AND ASTHMA REPORTS